ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 130 filers reported holding ASCENDIS PHARMA A/S in Q3 2019. The put-call ratio across all filers is 0.17 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $147 | +212.8% | 2 | -97.8% | 0.00% | – |
| Q2 2023 | $47 | -74.0% | 89 | -16.8% | 0.00% | -100.0% |
| Q1 2023 | $181 | +417.1% | 107 | -12.3% | 0.01% | – |
| Q4 2022 | $35 | -100.0% | 122 | -60.5% | 0.00% | -100.0% |
| Q3 2022 | $175,000 | +12.2% | 309 | +10.8% | 0.01% | +20.0% |
| Q2 2022 | $156,000 | -21.2% | 279 | -20.5% | 0.01% | -16.7% |
| Q1 2022 | $198,000 | -94.6% | 351 | -91.0% | 0.01% | -92.7% |
| Q4 2021 | $3,644,000 | +2191.8% | 3,915 | +14400.0% | 0.08% | +9.3% |
| Q3 2021 | $159,000 | +14.4% | 27 | -91.7% | 0.08% | -21.9% |
| Q4 2019 | $139,000 | +139.7% | 326 | -46.1% | 0.10% | +92.0% |
| Q3 2019 | $58,000 | -42.0% | 605 | -30.1% | 0.05% | -39.0% |
| Q2 2019 | $100,000 | -21.9% | 866 | -23.6% | 0.08% | -21.2% |
| Q1 2019 | $128,000 | – | 1,133 | +56550.0% | 0.10% | – |
| Q3 2018 | $0 | – | 2 | 0.0% | 0.00% | – |
| Q2 2018 | $0 | – | 2 | -33.3% | 0.00% | – |
| Q1 2018 | $0 | – | 3 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |